Canada markets closed

Chemomab Therapeutics Ltd. (CMMB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8390+0.0290 (+3.58%)
At close: 04:00PM EDT
0.8400 +0.00 (+0.12%)
After hours: 06:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8100
Open0.7900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7700 - 0.8450
52 Week Range0.4200 - 1.8900
Volume66,540
Avg. Volume249,838
Market Cap11.93M
Beta (5Y Monthly)-0.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

    ─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrollment Six Months Ahead of Schedule─ ─New Peer-Reviewed Publications Based on Patient Sample Studies Further Reinforce the Key Role of Chemomab’s Novel CCL24 Target in Both PSC and Systemic Sclerosis─ ─PSC Expert Webinar Highlights the Emerging Importance of Surrogate Biomarkers in PSC Clinical Devel

  • GlobeNewswire

    Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

    TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it received formal notification from the Listing Qualification Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it has been granted an additional 180-day compliance period, or until November 4, 2024, to regain complianc

  • GlobeNewswire

    Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

    TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the Aegis Virtual Conference on May 7, 2024 at 9:00 am ET. Dr. Mor’s presentation will be webcast live. The registration link to access the live presentation is included